FDA Panel Recommends Keeping GlaxoSmithKline’s Avandia On US Market, But With More Warnings, Restrictions

WASHINGTON (Dow Jones)--A Food and Drug Administration panel voted Wednesday to recommend that GlaxoSmithKline PLC's (GSK) diabetes drug, Avandia, remain on the market despite concerns the product could raise the risk of heart attacks.